Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark. / Pilemann-Lyberg, S; Thorsteinsson, B; Snorgaard, O; Zander, M; Vestergaard, H; Røder, M E.

In: Diabetes Research and Clinical Practice, Vol. 110, No. 2, 2015, p. 202-7.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Pilemann-Lyberg, S, Thorsteinsson, B, Snorgaard, O, Zander, M, Vestergaard, H & Røder, ME 2015, 'Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark', Diabetes Research and Clinical Practice, vol. 110, no. 2, pp. 202-7. https://doi.org/10.1016/j.diabres.2015.09.006

APA

Pilemann-Lyberg, S., Thorsteinsson, B., Snorgaard, O., Zander, M., Vestergaard, H., & Røder, M. E. (2015). Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark. Diabetes Research and Clinical Practice, 110(2), 202-7. https://doi.org/10.1016/j.diabres.2015.09.006

Vancouver

Pilemann-Lyberg S, Thorsteinsson B, Snorgaard O, Zander M, Vestergaard H, Røder ME. Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark. Diabetes Research and Clinical Practice. 2015;110(2):202-7. https://doi.org/10.1016/j.diabres.2015.09.006

Author

Pilemann-Lyberg, S ; Thorsteinsson, B ; Snorgaard, O ; Zander, M ; Vestergaard, H ; Røder, M E. / Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark. In: Diabetes Research and Clinical Practice. 2015 ; Vol. 110, No. 2. pp. 202-7.

Bibtex

@article{e40c9a860d3b42c0a6c2a36dd7484ea9,
title = "Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark",
abstract = "AIMS: Sulphonylureas (SU) are currently recommended as a well-established second line treatment in guidelines for type 2 diabetes (T2DM). In the Capital Region of Denmark 16,865 patients were given SU as part of their treatment of T2DM in 2010-2011. To what extent SU are associated with hospitalizations due to severe hypoglycaemic episodes, defined as episodes with a need for external assistance, was investigated. The prevalence and characteristics of these patients and potential risk factors were studied.METHODS: ICD-10 diagnosis codes were used to identify patients hospitalized due to hypoglycaemia and T2DM for a period of 2 years (2010-2011). Inclusion criteria were T2DM, hospitalization due to hypoglycaemia and treatment with SU as monotherapy or in combination with other glucose-lowering drugs except insulin treatment.RESULTS: We identified 161 patients fulfilling the inclusion criteria. Their mean age was 76 (53-97) years and 54{\%} were males. Sixty percent of the patients had diabetic complications, including 19{\%} with diabetic nephropathy. The major reason for severe hypoglycaemia was an unchanged dose of SU despite of a significant decline in food intake (45{\%}). In 22{\%} of the patients more than one reason was listed, most commonly a concomitant infection associated with decreased food intake and unchanged dose of SU.CONCLUSION: The incidence of hospital admission-requiring severe hypoglycaemia in patients treated with SU was 0.48 episodes per 100 patient-years of SU-treated patients. It was mainly older patients with diminished food intake, excessive alcohol use or other medications, concomitant infection, and with diabetic complications.",
author = "S Pilemann-Lyberg and B Thorsteinsson and O Snorgaard and M Zander and H Vestergaard and R{\o}der, {M E}",
note = "Copyright {\circledC} 2015 Elsevier Ireland Ltd. All rights reserved.",
year = "2015",
doi = "10.1016/j.diabres.2015.09.006",
language = "English",
volume = "110",
pages = "202--7",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark

AU - Pilemann-Lyberg, S

AU - Thorsteinsson, B

AU - Snorgaard, O

AU - Zander, M

AU - Vestergaard, H

AU - Røder, M E

N1 - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

PY - 2015

Y1 - 2015

N2 - AIMS: Sulphonylureas (SU) are currently recommended as a well-established second line treatment in guidelines for type 2 diabetes (T2DM). In the Capital Region of Denmark 16,865 patients were given SU as part of their treatment of T2DM in 2010-2011. To what extent SU are associated with hospitalizations due to severe hypoglycaemic episodes, defined as episodes with a need for external assistance, was investigated. The prevalence and characteristics of these patients and potential risk factors were studied.METHODS: ICD-10 diagnosis codes were used to identify patients hospitalized due to hypoglycaemia and T2DM for a period of 2 years (2010-2011). Inclusion criteria were T2DM, hospitalization due to hypoglycaemia and treatment with SU as monotherapy or in combination with other glucose-lowering drugs except insulin treatment.RESULTS: We identified 161 patients fulfilling the inclusion criteria. Their mean age was 76 (53-97) years and 54% were males. Sixty percent of the patients had diabetic complications, including 19% with diabetic nephropathy. The major reason for severe hypoglycaemia was an unchanged dose of SU despite of a significant decline in food intake (45%). In 22% of the patients more than one reason was listed, most commonly a concomitant infection associated with decreased food intake and unchanged dose of SU.CONCLUSION: The incidence of hospital admission-requiring severe hypoglycaemia in patients treated with SU was 0.48 episodes per 100 patient-years of SU-treated patients. It was mainly older patients with diminished food intake, excessive alcohol use or other medications, concomitant infection, and with diabetic complications.

AB - AIMS: Sulphonylureas (SU) are currently recommended as a well-established second line treatment in guidelines for type 2 diabetes (T2DM). In the Capital Region of Denmark 16,865 patients were given SU as part of their treatment of T2DM in 2010-2011. To what extent SU are associated with hospitalizations due to severe hypoglycaemic episodes, defined as episodes with a need for external assistance, was investigated. The prevalence and characteristics of these patients and potential risk factors were studied.METHODS: ICD-10 diagnosis codes were used to identify patients hospitalized due to hypoglycaemia and T2DM for a period of 2 years (2010-2011). Inclusion criteria were T2DM, hospitalization due to hypoglycaemia and treatment with SU as monotherapy or in combination with other glucose-lowering drugs except insulin treatment.RESULTS: We identified 161 patients fulfilling the inclusion criteria. Their mean age was 76 (53-97) years and 54% were males. Sixty percent of the patients had diabetic complications, including 19% with diabetic nephropathy. The major reason for severe hypoglycaemia was an unchanged dose of SU despite of a significant decline in food intake (45%). In 22% of the patients more than one reason was listed, most commonly a concomitant infection associated with decreased food intake and unchanged dose of SU.CONCLUSION: The incidence of hospital admission-requiring severe hypoglycaemia in patients treated with SU was 0.48 episodes per 100 patient-years of SU-treated patients. It was mainly older patients with diminished food intake, excessive alcohol use or other medications, concomitant infection, and with diabetic complications.

U2 - 10.1016/j.diabres.2015.09.006

DO - 10.1016/j.diabres.2015.09.006

M3 - Journal article

VL - 110

SP - 202

EP - 207

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -

ID: 147661759